{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:52:21Z","timestamp":1793242341974,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.ophtha.2009.09.049","type":"journal-article","created":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T09:08:54Z","timestamp":1262682534000},"page":"861-869","source":"Crossref","is-referenced-by-count":144,"title":["Combination of Rituximab and Intravenous Immunoglobulin for Recalcitrant Ocular Cicatricial Pemphigoid"],"prefix":"10.1016","volume":"117","author":[{"given":"C. Stephen","family":"Foster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Y.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Razzaque","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2009.09.049_bib1","first-page":"527","article-title":"Cicatricial pemphigoid","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ophtha.2009.09.049_bib2","doi-asserted-by":"crossref","first-page":"11579","DOI":"10.1073\/pnas.88.24.11579","article-title":"Association of DQw7 (DQB1*0301) with ocular cicatricial pemphigoid","volume":"88","author":"Ahmed","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2009.09.049_bib3","doi-asserted-by":"crossref","first-page":"7747","DOI":"10.1073\/pnas.91.16.7747","article-title":"Common major histocompatibility complex class II markers in clinical variants of cicatricial pemphigoid","volume":"91","author":"Yunis","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2009.09.049_bib4","first-page":"330","article-title":"HLA-DRB1 and HLA-DQB1 genes in susceptibility and resistance to cicatricial pemphigoid in French Caucasians","volume":"8","author":"Drouet","year":"1998","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ophtha.2009.09.049_bib5","doi-asserted-by":"crossref","first-page":"14714","DOI":"10.1073\/pnas.93.25.14714","article-title":"Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization","volume":"93","author":"Tyagi","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2009.09.049_bib6","first-page":"2283","article-title":"The role of antibody to human beta4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid","volume":"40","author":"Chan","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2009.09.049_bib7","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.4049\/jimmunol.165.5.2824","article-title":"The autoantibodies to alpha 6 beta 4 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human beta 4","volume":"165","author":"Bhol","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.ophtha.2009.09.049_bib8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0161-6420(82)34791-0","article-title":"Immunosuppressive therapy for progressive ocular cicatricial pemphigoid","volume":"89","author":"Foster","year":"1982","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2009.09.049_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0161-6420(01)00863-6","article-title":"The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid","volume":"109","author":"Miserocchi","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2009.09.049_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2007.04.027","article-title":"Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes","volume":"115","author":"Saw","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2009.09.049_bib11","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2008.08.002","article-title":"Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy","volume":"115","author":"Thorne","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2009.09.049_bib12","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/S0161-6420(99)90496-7","article-title":"Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study","volume":"106","author":"Foster","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2009.09.049_bib13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.ophtha.2003.11.012","article-title":"Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up","volume":"111","author":"Sami","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2009.09.049_bib14","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2009.09.049_bib15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archderm.139.8.1051","article-title":"Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases","volume":"139","author":"Ahmed","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ophtha.2009.09.049_bib16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2009.09.049_bib17","first-page":"1","article-title":"Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: a comprehensive survey of 71 consecutive patients from the initial use to 2007","volume":"5","author":"Peterson","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ophtha.2009.09.049_bib18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/bjo.2007.129510","article-title":"The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement","volume":"93","author":"Ross","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2009.09.049_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2340\/00015555-0560","article-title":"Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab [letter]","volume":"89","author":"Schumann","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ophtha.2009.09.049_bib20","first-page":"731","article-title":"Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab","volume":"6","author":"Taverna","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ophtha.2009.09.049_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ophtha.2009.09.049_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"G\u00fcrcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ophtha.2009.09.049_bib23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2006.05.009","article-title":"Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris","volume":"55","author":"El Tal","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ophtha.2009.09.049_bib24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2009.09.049_bib25","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1345\/aph.1E595","article-title":"Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study","volume":"39","author":"Daoud","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ophtha.2009.09.049_bib26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.intimp.2005.11.002","article-title":"Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases","volume":"6","author":"Daoud","year":"2006","journal-title":"Int Immunopharmacol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642009011622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642009011622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T05:28:08Z","timestamp":1544765288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642009011622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0161642009011622"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2009.09.049","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}